Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Myositis associated with carbon monoxide poisoning.

Weaver LK, Oliver LC, Deru K, Stemmer-Rachamimov AO.

Undersea Hyperb Med. 2019 Jan-Feb;46(1):63-67.

PMID:
31154686
2.

Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1.

Isakson SH, Rizzardi AE, Coutts AW, Carlson DF, Kirstein MN, Fisher J, Vitte J, Williams KB, Pluhar GE, Dahiya S, Widemann BC, Dombi E, Rizvi T, Ratner N, Messiaen L, Stemmer-Rachamimov AO, Fahrenkrug SC, Gutmann DH, Giovannini M, Moertel CL, Largaespada DA, Watson AL.

Commun Biol. 2018 Oct 2;1:158. doi: 10.1038/s42003-018-0163-y. eCollection 2018.

3.

DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome.

Juratli TA, McCabe D, Nayyar N, Williams EA, Silverman IM, Tummala SS, Fink AL, Baig A, Martinez-Lage M, Selig MK, Bihun IV, Shankar GM, Penson T, Lastrapes M, Daubner D, Meinhardt M, Hennig S, Kaplan AB, Fujio S, Kuter BM, Bertalan MS, Miller JJ, Batten JM, Ely HA, Christiansen J, Baretton GB, Stemmer-Rachamimov AO, Santagata S, Rivera MN, Barker FG 2nd, Schackert G, Wakimoto H, Iafrate AJ, Carter SL, Cahill DP, Brastianos PK.

Acta Neuropathol. 2018 Nov;136(5):779-792. doi: 10.1007/s00401-018-1899-7. Epub 2018 Aug 19.

PMID:
30123936
4.

Virus vector-mediated genetic modification of brain tumor stromal cells after intravenous delivery.

Volak A, LeRoy SG, Natasan JS, Park DJ, Cheah PS, Maus A, Fitzpatrick Z, Hudry E, Pinkham K, Gandhi S, Hyman BT, Mu D, GuhaSarkar D, Stemmer-Rachamimov AO, Sena-Esteves M, Badr CE, Maguire CA.

J Neurooncol. 2018 Sep;139(2):293-305. doi: 10.1007/s11060-018-2889-2. Epub 2018 May 16.

5.

Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.

Wu LMN, Deng Y, Wang J, Zhao C, Wang J, Rao R, Xu L, Zhou W, Choi K, Rizvi TA, Remke M, Rubin JB, Johnson RL, Carroll TJ, Stemmer-Rachamimov AO, Wu J, Zheng Y, Xin M, Ratner N, Lu QR.

Cancer Cell. 2018 Feb 12;33(2):292-308.e7. doi: 10.1016/j.ccell.2018.01.005.

6.

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Cañadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA.

Cancer Discov. 2018 Feb;8(2):196-215. doi: 10.1158/2159-8290.CD-17-0833. Epub 2017 Nov 3.

7.

Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas.

Kim D, Niemierko A, Hwang WL, Stemmer-Rachamimov AO, Curry WT, Barker FG, Martuza RL, Oh KS, Loeffler JS, Shih HA.

J Neurosurg. 2018 Apr;128(4):1123-1132. doi: 10.3171/2016.11.JNS16913. Epub 2017 Jun 16.

PMID:
28621619
8.

Identification of RUNX1 as a Mediator of Aberrant Retinal Angiogenesis.

Lam JD, Oh DJ, Wong LL, Amarnani D, Park-Windhol C, Sanchez AV, Cardona-Velez J, McGuone D, Stemmer-Rachamimov AO, Eliott D, Bielenberg DR, van Zyl T, Shen L, Gai X, D'Amore PA, Kim LA, Arboleda-Velasquez JF.

Diabetes. 2017 Jul;66(7):1950-1956. doi: 10.2337/db16-1035. Epub 2017 Apr 11.

9.

Immunoevasion rather than intrinsic oncogenicity may confer MSCs from non-obese diabetic mice the ability to generate neural tumors.

Loretelli C, Moore RF, Ben Nasr M, Dellepiane S, Balan M, Mounayar M, Usuelli V, El Essawy B, D'Addio F, Stemmer-Rachamimov AO, Zuccotti GV, Pal S, Fiorina P, Abdi R.

Acta Diabetol. 2017 Jul;54(7):707-712. doi: 10.1007/s00592-017-0967-0. Epub 2017 Feb 21. No abstract available.

PMID:
28224274
10.

Olig2-Dependent Reciprocal Shift in PDGF and EGF Receptor Signaling Regulates Tumor Phenotype and Mitotic Growth in Malignant Glioma.

Lu F, Chen Y, Zhao C, Wang H, He D, Xu L, Wang J, He X, Deng Y, Lu EE, Liu X, Verma R, Bu H, Drissi R, Fouladi M, Stemmer-Rachamimov AO, Burns D, Xin M, Rubin JB, Bahassi EM, Canoll P, Holland EC, Lu QR.

Cancer Cell. 2016 May 9;29(5):669-683. doi: 10.1016/j.ccell.2016.03.027.

11.

Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.

Wu J, Keng VW, Patmore DM, Kendall JJ, Patel AV, Jousma E, Jessen WJ, Choi K, Tschida BR, Silverstein KA, Fan D, Schwartz EB, Fuchs JR, Zou Y, Kim MO, Dombi E, Levy DE, Huang G, Cancelas JA, Stemmer-Rachamimov AO, Spinner RJ, Largaespada DA, Ratner N.

Cell Rep. 2016 Mar 1;14(8):1979-90. doi: 10.1016/j.celrep.2016.01.074. Epub 2016 Feb 18.

12.

Insulator dysfunction and oncogene activation in IDH mutant gliomas.

Flavahan WA, Drier Y, Liau BB, Gillespie SM, Venteicher AS, Stemmer-Rachamimov AO, Suvà ML, Bernstein BE.

Nature. 2016 Jan 7;529(7584):110-4. doi: 10.1038/nature16490. Epub 2015 Dec 23.

13.

Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade.

Hwang WL, Marciscano AE, Niemierko A, Kim DW, Stemmer-Rachamimov AO, Curry WT, Barker FG 2nd, Martuza RL, Loeffler JS, Oh KS, Shih HA, Larvie M.

Neuro Oncol. 2016 Jun;18(6):863-72. doi: 10.1093/neuonc/nov285. Epub 2015 Nov 22.

14.

Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model.

Gao X, Zhao Y, Stemmer-Rachamimov AO, Liu H, Huang P, Chin S, Selig MK, Plotkin SR, Jain RK, Xu L.

Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):14676-81. doi: 10.1073/pnas.1512570112. Epub 2015 Nov 9.

15.

Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes.

Marciscano AE, Stemmer-Rachamimov AO, Niemierko A, Larvie M, Curry WT, Barker FG 2nd, Martuza RL, McGuone D, Oh KS, Loeffler JS, Shih HA.

J Neurosurg. 2016 Jan;124(1):106-14. doi: 10.3171/2015.1.JNS142228. Epub 2015 Aug 14.

PMID:
26274991
16.

Characterization of cells from patient-derived fibrovascular membranes in proliferative diabetic retinopathy.

Kim LA, Wong LL, Amarnani DS, Bigger-Allen AA, Hu Y, Marko CK, Eliott D, Shah VA, McGuone D, Stemmer-Rachamimov AO, Gai X, D'Amore PA, Arboleda-Velasquez JF.

Mol Vis. 2015 Jun 12;21:673-87. eCollection 2015.

17.

Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2.

Stivaros SM, Stemmer-Rachamimov AO, Alston R, Plotkin SR, Nadol JB, Quesnel A, O'Malley J, Whitfield GA, McCabe MG, Freeman SR, Lloyd SK, Wright NB, Kilday JP, Kamaly-Asl ID, Mills SJ, Rutherford SA, King AT, Evans DG.

J Med Genet. 2015 Aug;52(8):557-62. doi: 10.1136/jmedgenet-2015-103050. Epub 2015 Jun 23.

18.

Sporadic hemangioblastomas are characterized by cryptic VHL inactivation.

Shankar GM, Taylor-Weiner A, Lelic N, Jones RT, Kim JC, Francis JM, Abedalthagafi M, Borges LF, Coumans JV, Curry WT, Nahed BV, Shin JH, Paek SH, Park SH, Stewart C, Lawrence MS, Cibulskis K, Thorner AR, Van Hummelen P, Stemmer-Rachamimov AO, Batchelor TT, Carter SL, Hoang MP, Santagata S, Louis DN, Barker FG, Meyerson M, Getz G, Brastianos PK, Cahill DP.

Acta Neuropathol Commun. 2014 Dec 24;2:167. doi: 10.1186/s40478-014-0167-x.

19.

Update from the 2013 International Neurofibromatosis Conference.

Plotkin SR, Albers AC, Babovic-Vuksanovic D, Blakeley JO, Breakefield XO, Dunn CM, Evans DG, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Kalamarides M, McClatchey AI, Messiaen L, Morrison H, Parkinson DB, Stemmer-Rachamimov AO, Van Raamsdonk CD, Riccardi VM, Rosser T, Schindeler A, Smith MJ, Stevenson DA, Ullrich NJ, van der Vaart T, Weiss B, Widemann BC, Zhu Y, Bakker AC, Lloyd AC.

Am J Med Genet A. 2014 Dec;164A(12):2969-78. doi: 10.1002/ajmg.a.36754. Epub 2014 Sep 24. No abstract available.

20.

Turner syndrome and meningioma: support for a possible increased risk of neoplasia in Turner syndrome.

Pier DB, Nunes FP, Plotkin SR, Stemmer-Rachamimov AO, Kim JC, Shih HA, Brastianos P, Lin AE.

Eur J Med Genet. 2014 May-Jun;57(6):269-74. doi: 10.1016/j.ejmg.2014.03.005. Epub 2014 Mar 25.

PMID:
24675142
21.

Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.

Antoszczyk S, Spyra M, Mautner VF, Kurtz A, Stemmer-Rachamimov AO, Martuza RL, Rabkin SD.

Neuro Oncol. 2014 Aug;16(8):1057-66. doi: 10.1093/neuonc/not317. Epub 2014 Jan 26.

22.

A 50-year-old man with a long-standing, large-angle exotropia and limitation of adduction in the left eye.

Mehendale RA, Stemmer-Rachamimov AO, Dagi LR.

Digit J Ophthalmol. 2013 Dec 30;19(4):64-7. doi: 10.5693/djo.03.2013.09.004. eCollection 2013. No abstract available.

23.

Nf1 loss and Ras hyperactivation in oligodendrocytes induce NOS-driven defects in myelin and vasculature.

Mayes DA, Rizvi TA, Titus-Mitchell H, Oberst R, Ciraolo GM, Vorhees CV, Robinson AP, Miller SD, Cancelas JA, Stemmer-Rachamimov AO, Ratner N.

Cell Rep. 2013 Sep 26;4(6):1197-212. doi: 10.1016/j.celrep.2013.08.011. Epub 2013 Sep 12.

24.

Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.

Lu-Emerson C, Snuderl M, Kirkpatrick ND, Goveia J, Davidson C, Huang Y, Riedemann L, Taylor J, Ivy P, Duda DG, Ancukiewicz M, Plotkin SR, Chi AS, Gerstner ER, Eichler AF, Dietrich J, Stemmer-Rachamimov AO, Batchelor TT, Jain RK.

Neuro Oncol. 2013 Aug;15(8):1079-87. doi: 10.1093/neuonc/not082. Epub 2013 Jul 4.

25.

Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.

Zhang W, Fulci G, Wakimoto H, Cheema TA, Buhrman JS, Jeyaretna DS, Stemmer Rachamimov AO, Rabkin SD, Martuza RL.

Neoplasia. 2013 Jun;15(6):591-9.

26.

Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.

Plotkin SR, Blakeley JO, Evans DG, Hanemann CO, Hulsebos TJ, Hunter-Schaedle K, Kalpana GV, Korf B, Messiaen L, Papi L, Ratner N, Sherman LS, Smith MJ, Stemmer-Rachamimov AO, Vitte J, Giovannini M.

Am J Med Genet A. 2013 Mar;161A(3):405-16. doi: 10.1002/ajmg.a.35760. Epub 2013 Feb 7.

27.

Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.

Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, Ligon KL, Palescandolo E, Van Hummelen P, Ducar MD, Raza A, Sunkavalli A, Macconaill LE, Stemmer-Rachamimov AO, Louis DN, Hahn WC, Dunn IF, Beroukhim R.

Nat Genet. 2013 Mar;45(3):285-9. doi: 10.1038/ng.2526. Epub 2013 Jan 20.

28.

EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors.

Wu J, Patmore DM, Jousma E, Eaves DW, Breving K, Patel AV, Schwartz EB, Fuchs JR, Cripe TP, Stemmer-Rachamimov AO, Ratner N.

Oncogene. 2014 Jan 9;33(2):173-80. doi: 10.1038/onc.2012.579. Epub 2013 Jan 14.

29.

Decreased vision and junctional scotoma from pituicytoma.

Huynh N, Stemmer-Rachamimov AO, Swearingen B, Cestari DM.

Case Rep Ophthalmol. 2012 May;3(2):190-6. doi: 10.1159/000339242. Epub 2012 May 30.

30.

Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.

James MF, Stivison E, Beauchamp R, Han S, Li H, Wallace MR, Gusella JF, Stemmer-Rachamimov AO, Ramesh V.

Mol Cancer Res. 2012 May;10(5):649-59. doi: 10.1158/1541-7786.MCR-11-0425-T. Epub 2012 Mar 16.

31.

Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated gliomas to be spinal ependymomas.

Hagel C, Stemmer-Rachamimov AO, Bornemann A, Schuhmann M, Nagel C, Huson S, Evans DG, Plotkin S, Matthies C, Kluwe L, Mautner VF.

Neuropathology. 2012 Dec;32(6):611-6. doi: 10.1111/j.1440-1789.2012.01306.x. Epub 2012 Mar 7.

PMID:
22394059
32.

An intraoperative multimodal neurophysiologic approach to successful resection of precentral gyrus epileptogenic lesions.

Simon MV, Cole AJ, Chang EC, Buchbinder BR, Stufflebeam SM, Nozari A, Stemmer-Rachamimov AO, Eskandar EN.

Epilepsia. 2012 Apr;53(4):e75-9. doi: 10.1111/j.1528-1167.2011.03400.x. Epub 2012 Feb 6.

33.

Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.

Blakeley JO, Evans DG, Adler J, Brackmann D, Chen R, Ferner RE, Hanemann CO, Harris G, Huson SM, Jacob A, Kalamarides M, Karajannis MA, Korf BR, Mautner VF, McClatchey AI, Miao H, Plotkin SR, Slattery W 3rd, Stemmer-Rachamimov AO, Welling DB, Wen PY, Widemann B, Hunter-Schaedle K, Giovannini M.

Am J Med Genet A. 2012 Jan;158A(1):24-41. doi: 10.1002/ajmg.a.34359. Epub 2011 Dec 2.

34.

Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.

Wakimoto H, Mohapatra G, Kanai R, Curry WT Jr, Yip S, Nitta M, Patel AP, Barnard ZR, Stemmer-Rachamimov AO, Louis DN, Martuza RL, Rabkin SD.

Neuro Oncol. 2012 Feb;14(2):132-44. doi: 10.1093/neuonc/nor195. Epub 2011 Nov 7.

35.

Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex.

Larson AM, Hedgire SS, Deshpande V, Stemmer-Rachamimov AO, Harisinghani MG, Ferrone CR, Shah U, Thiele EA.

Clin Genet. 2012 Dec;82(6):558-63. doi: 10.1111/j.1399-0004.2011.01805.x. Epub 2011 Nov 29.

PMID:
22035404
36.

Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.

Zhang W, Fulci G, Buhrman JS, Stemmer-Rachamimov AO, Chen JW, Wojtkiewicz GR, Weissleder R, Rabkin SD, Martuza RL.

Mol Ther. 2012 Jan;20(1):37-45. doi: 10.1038/mt.2011.187. Epub 2011 Sep 13.

37.

Distinguishing inflammation from tumor and peritumoral edema by myeloperoxidase magnetic resonance imaging.

Kleijn A, Chen JW, Buhrman JS, Wojtkiewicz GR, Iwamoto Y, Lamfers ML, Stemmer-Rachamimov AO, Rabkin SD, Weissleder R, Martuza RL, Fulci G.

Clin Cancer Res. 2011 Jul 1;17(13):4484-93. doi: 10.1158/1078-0432.CCR-11-0575. Epub 2011 May 10.

38.

Perinatal or adult Nf1 inactivation using tamoxifen-inducible PlpCre each cause neurofibroma formation.

Mayes DA, Rizvi TA, Cancelas JA, Kolasinski NT, Ciraolo GM, Stemmer-Rachamimov AO, Ratner N.

Cancer Res. 2011 Jul 1;71(13):4675-85. doi: 10.1158/0008-5472.CAN-10-4558. Epub 2011 May 6.

39.

Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes.

Kalamarides M, Stemmer-Rachamimov AO, Niwa-Kawakita M, Chareyre F, Taranchon E, Han ZY, Martinelli C, Lusis EA, Hegedus B, Gutmann DH, Giovannini M.

Oncogene. 2011 May 19;30(20):2333-44. doi: 10.1038/onc.2010.609. Epub 2011 Jan 17.

PMID:
21242963
40.

Superficial neurofibromas in the setting of schwannomatosis: nosologic implications.

Rodriguez FJ, Scheithauer BW, George D, Midha R, MacCollin M, Stemmer-Rachamimov AO.

Acta Neuropathol. 2011 May;121(5):663-8. doi: 10.1007/s00401-010-0793-8. Epub 2010 Dec 30.

41.

miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways.

Saydam O, Senol O, Würdinger T, Mizrak A, Ozdener GB, Stemmer-Rachamimov AO, Yi M, Stephens RM, Krichevsky AM, Saydam N, Brenner GJ, Breakefield XO.

Cancer Res. 2011 Feb 1;71(3):852-61. doi: 10.1158/0008-5472.CAN-10-1219. Epub 2010 Dec 13.

42.

A novel imaging-compatible sciatic nerve schwannoma model.

Saydam O, Ozdener GB, Senol O, Mizrak A, Prabhakar S, Stemmer-Rachamimov AO, Breakefield XO, Brenner GJ.

J Neurosci Methods. 2011 Jan 30;195(1):75-7. doi: 10.1016/j.jneumeth.2010.10.021. Epub 2010 Nov 24.

43.

Comparative protein profiling reveals minichromosome maintenance (MCM) proteins as novel potential tumor markers for meningiomas.

Saydam O, Senol O, Schaaij-Visser TB, Pham TV, Piersma SR, Stemmer-Rachamimov AO, Wurdinger T, Peerdeman SM, Jimenez CR.

J Proteome Res. 2010 Jan;9(1):485-94. doi: 10.1021/pr900834h.

44.

Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.

Saydam O, Shen Y, Würdinger T, Senol O, Boke E, James MF, Tannous BA, Stemmer-Rachamimov AO, Yi M, Stephens RM, Fraefel C, Gusella JF, Krichevsky AM, Breakefield XO.

Mol Cell Biol. 2009 Nov;29(21):5923-40. doi: 10.1128/MCB.00332-09. Epub 2009 Aug 24.

45.

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.

Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E.

N Engl J Med. 2009 Jul 23;361(4):358-67. doi: 10.1056/NEJMoa0902579. Epub 2009 Jul 8.

46.

Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis.

McGillicuddy LT, Fromm JA, Hollstein PE, Kubek S, Beroukhim R, De Raedt T, Johnson BW, Williams SM, Nghiemphu P, Liau LM, Cloughesy TF, Mischel PS, Parret A, Seiler J, Moldenhauer G, Scheffzek K, Stemmer-Rachamimov AO, Sawyers CL, Brennan C, Messiaen L, Mellinghoff IK, Cichowski K.

Cancer Cell. 2009 Jul 7;16(1):44-54. doi: 10.1016/j.ccr.2009.05.009.

47.

Genetic determinants of hearing loss associated with vestibular schwannomas.

Stankovic KM, Mrugala MM, Martuza RL, Silver M, Betensky RA, Nadol JB Jr, Stemmer-Rachamimov AO.

Otol Neurotol. 2009 Aug;30(5):661-7. doi: 10.1097/MAO.0b013e3181a66ece.

PMID:
19546833
48.

NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.

James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO, Gusella JF, Ramesh V.

Mol Cell Biol. 2009 Aug;29(15):4250-61. doi: 10.1128/MCB.01581-08. Epub 2009 May 18.

49.

Ependymoma of the sella turcica: a variant of pituicytoma.

Scheithauer BW, Swearingen B, Whyte ET, Auluck PK, Stemmer-Rachamimov AO.

Hum Pathol. 2009 Mar;40(3):435-40. doi: 10.1016/j.humpath.2008.08.013. Epub 2008 Nov 7.

PMID:
18992914
50.

A role for the p53 pathway in the pathology of meningiomas with NF2 loss.

Chang Z, Guo CL, Ahronowitz I, Stemmer-Rachamimov AO, MacCollin M, Nunes FP.

J Neurooncol. 2009 Feb;91(3):265-70. doi: 10.1007/s11060-008-9721-3. Epub 2008 Nov 1.

Supplemental Content

Loading ...
Support Center